title: Medication adherence and readmission after myocardial infarction in the Medicare population.
abstract: OBJECTIVE
  To examine the relationship between 6-month medication adherence and 1-year downstream heart disease-related readmission among patients who survived a myocardial infarction (MI).
  
  
  METHODS
  Retrospective, nested case-control analysis of Medicare fee-for-service beneficiaries who were discharged alive post MI in 2008 (n = 168,882).
  
  
  METHODS
  Patients in the case group had their first heart-disease-related readmission post MI discharge during the 6-to-9-month period or the 9-to-12-month period. We then used propensity score matching to identify patients in the control group who had similar characteristics, but did not have a readmission in the same time window. Adherence was defined as the average 6-month medication possession ratio (MPR) prior to the first date of the time-window defining readmission.
  
  
  RESULTS
  After controlling for demographics, insurance coverage, and clinical characteristics, patients who had a heart-disease-related readmission had worse adherence, with MPRs of 0.70 and 0.74 in the case and control groups, respectively. Odds ratio of MPR ≥ 0.75 was 0.79 (95% CI, 0.75-0.83) among those with a readmission relative to those without.
  
  
  CONCLUSIONS
  Our study shows that better 6-month medication adherence may reduce heart-disease-related readmissions within a year after an MI.
authors: Yuting
authors: Y
authors: Zhang
authors: Cameron M
authors: CM
authors: Kaplan
authors: Seo Hyon
authors: SH
authors: Baik
authors: Chung-Chou H
authors: CC
authors: Chang
authors: Judith R
authors: JR
authors: Lave
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008297:Male; D006278:Medicare / Q000706:statistics & numerical data*; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000523:psychology; D010359:Patient Readmission / Q000706:statistics & numerical data*; D057216:Propensity Score; D012189:Retrospective Studies; D014481:United States; D016903:Drug Monitoring
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
references: Med Care. 2005 Jun;43(6):521-30
references: 15908846
references: N Engl J Med. 2011 Dec 1;365(22):2088-97
references: 22080794
references: N Engl J Med. 2012 Apr 12;366(15):1366-9
references: 22455752
references: BMJ. 2003 Jun 28;326(7404):1419
references: 12829553
references: Stat Sci. 2007;22(4):569-573
references: 18516239
references: N Engl J Med. 2009 Apr 2;360(14):1418-28
references: 19339721
references: Med Care. 2010 May;48(5):409-17
references: 20393360
references: Circulation. 2011 Feb 1;123(4):e18-e209
references: 21160056
references: Am Heart J. 2011 Aug;162(2):254-261.e3
references: 21835285
references: Health Aff (Millwood). 2011 Jan;30(1):91-9
references: 21209444
references: Circulation. 2008 Jan 15;117(2):296-329
references: 18071078
references: Circulation. 2008 Mar 11;117(10):1261-8
references: 18285564
references: Health Serv Res. 2011 Aug;46(4):1180-99
references: 21413981
references: JAMA. 2011 Feb 16;305(7):675-81
references: 21325183